Holen Sie sich die Stockscreener-App
3.70
2.37%
-0.09
Handel nachbörslich:
4.20
0.50
+13.51%
Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Nasdaq Delisting Risk Eliminated: Dogwood Therapeutics Secures Future with $17.5M War Chest - Stock Titan
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan
Endo's $99M Strategic Sale: International Pharma Division Goes to Knight Therapeutics - Stock Titan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan
How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan
Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan
When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - Stock Titan
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan
Can This New Estée Lauder Partnership Transform How Your Skin Ages? - Stock Titan
Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan
Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - Stock Titan
Can KalVista's March Conference Circuit Signal Major Pipeline Updates? - Stock Titan
Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan
Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan
Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - Stock Titan
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan
Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan
Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - Stock Titan
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan
Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan
Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal - Stock Titan
Critical Safety Signal Emerges: Pliant's IPF Drug Trial Faces Unexpected DSMB Intervention - StockTitan
Breakthrough NPC1 Treatment Data: 87% of Young Patients Show Recovery Signs in Cyclo Trial - StockTitan
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
TFF Pharmaceuticals to Exit Nasdaq: Complete Liquidation Plan Leaves Shareholders in Limbo - StockTitan
Major Biotech Conferences Alert: NRx Pharmaceuticals Sets Stage for Key Industry Updates - StockTitan
Oncology & Obesity Pipeline Update: Terns Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan
Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan
KalVista Pharmaceutical's Major Talent Push: 261,000 Stock Options Awarded in Strategic Growth Move - StockTitan
Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - Stock Titan
Nasdaq Delisting Drama: Universe Pharmaceuticals Given 7 Days to Save Its Listing - StockTitan
X4 Pharma's Latest Employee Stock Plan: Strategic Move to Attract Top Talent - StockTitan
Mental Health Revolution: HOPE's $27M Backed Ketamine Clinic Network Takes Shape With BTIG Partnership - StockTitan
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - Stock Titan
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):